These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30006934)

  • 1. The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Storebø OJ; Faltinsen E; Zwi M; Simonsen E; Gluud C
    Clin Pharmacol Ther; 2018 Oct; 104(4):606-609. PubMed ID: 30006934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Getting to Long-Term Effectiveness and Safety of Attention-deficit Hyperactivity Disorder Medications.
    Beau-Lejdstrom R; Zito JM
    Clin Pharmacol Ther; 2018 Oct; 104(4):610-612. PubMed ID: 30120774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review.
    Froehlich TE; Fogler J; Barbaresi WJ; Elsayed NA; Evans SW; Chan E
    Clin Pharmacol Ther; 2018 Oct; 104(4):619-637. PubMed ID: 30053315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating a Child With Mental Illness.
    Ito S
    Clin Pharmacol Ther; 2018 Oct; 104(4):592-594. PubMed ID: 30222188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.
    Schweren LJ; de Zeeuw P; Durston S
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1151-64. PubMed ID: 23165220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 9. Responses to methylphenidate in Attention-Deficit/Hyperactivity Disorder and normal children: update 2002.
    Rapoport JL; Inoff-Germain G
    J Atten Disord; 2002; 6 Suppl 1():S57-60. PubMed ID: 12685519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questioning the treatment for ADHD.
    Breggin PR
    Science; 2001 Jan; 291(5504):595. PubMed ID: 11229399
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.
    Greenhill L; Beyer DH; Finkleson J; Shaffer D; Biederman J; Conners CK; Gillberg C; Huss M; Jensen P; Kennedy JL; Klein R; Rapoport J; Sagvolden T; Spencer T; Swanson JM; Volkow N
    J Atten Disord; 2002; 6 Suppl 1():S89-100. PubMed ID: 12685523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 15. Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea.
    Park S; Kim JW; Kim BN; Shin MS; Yoo HJ; Cho SC
    J Psychopharmacol; 2014 Jul; 28(7):671-6. PubMed ID: 24763183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the evidence base of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder flawed?
    Hoekstra PJ; Buitelaar JK
    Eur Child Adolesc Psychiatry; 2016 Apr; 25(4):339-40. PubMed ID: 27021055
    [No Abstract]   [Full Text] [Related]  

  • 17. Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.
    Nikles CJ; McKinlay L; Mitchell GK; Carmont SA; Senior HE; Waugh MC; Epps A; Schluter PJ; Lloyd OT
    Trials; 2014 Feb; 15():54. PubMed ID: 24524676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of methylphenidate-OROS
    Rausch TL; Kendall DL; Kover ST; Louw EM; Zsilavecz UL; Van der Merwe A
    S Afr J Commun Disord; 2017 Feb; 64(1):e1-e12. PubMed ID: 28281767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The answerable question and a hierarchy of evidence.
    Hamilton J
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):596-600. PubMed ID: 15908843
    [No Abstract]   [Full Text] [Related]  

  • 20. Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD).
    Ghanizadeh A
    Psychopharmacology (Berl); 2009 Mar; 203(1):185-6, author reply 187. PubMed ID: 19137280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.